01—Abstract
Summary
Summary of the 10-K filed February 21, 2020. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories' 2019 10-K filing reveals a company focused on strategic growth and portfolio diversification, highlighted by significant acquisitions in 2017, specifically St. Jude Medical and Alere.
The company operates across four key segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, with international sales comprising a substantial 64%a of its net sales in 2019. Abbott demonstrated robust sales growth across its segments, driven by new product introductions, market penetration, and the integration of recent acquisitions. The company also highlighted its commitment to shareholder returns through a 14% increase in declared dividends per share and ongoing share repurchase programs.
The filing also details Abbott's ongoing investments in research and development, focusing on next-generation technologies and product enhancements within its core segments. Despite a competitive and highly regulated healthcare landscape, Abbott's financial review indicates a strong operational performance, with improvements in gross profit margins and a focused approach to cost management. The company also detailed its capital structure, including significant debt management activities and a commitment to maintaining an investment-grade credit rating.
02—Key points
Key Highlights
- Abbott Laboratories reported robust sales growth across its four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
- International sales accounted for approximately 64% of consolidated net sales in 2019, underscoring the company's global presence.
- The Medical Devices segment saw strong growth, driven by key product areas like Diabetes Care (FreeStyle Libre), Structural Heart (MitraClip), Electrophysiology, and Heart Failure (HeartMate 3).
- Diagnostic Products revenue was boosted by the continued adoption of the Alinity suite of diagnostic instruments and strong performance in Core Laboratory and Rapid Diagnostics.
- The company declared dividends of $1.32 per share in 2019, a 14% increase from the prior year, reflecting a commitment to shareholder returns.
- Abbott continued to invest in R&D, focusing on innovation across all segments, with Medical Devices and Diagnostics receiving significant attention for new product development.
- The company actively managed its debt, reducing its total debt to $18.1 billion by the end of 2019 through various repayment and refinancing activities.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2019, Abbott Laboratories kept $0.12.
- Revenue$31.90B100.0%
- Cost of revenue−$13.23B41.5%
- Gross profit$18.67B58.5%
- Operating costs−$14.14B44.3%
- Operating income$4.53B14.2%
- Interest, other & tax−$845.0M2.6%
- Net income$3.69B11.6%
Where FY2019 revenue went
$31.90B- Cost of revenue: $13.23B, 41% of revenue
- SG&A: $9.77B, 31% of revenue
- Net income: $3.69B, 12% of revenue
- R&D: $2.44B, 7.6% of revenue
- Other operating costs: $1.94B, 6.1% of revenue
- Interest, other & tax: $845.0M, 2.6% of revenue
Kept 12% as net incomeNet income $3.69B · 12%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2019filed February 21, 2020Financial Statements
FY2019 against FY2018
| Line item | FY2019FY2018 | Change |
|---|---|---|
| Revenue | $31.90B$30.58B | +4.3% |
| Cost of Revenue | $13.23B$12.71B | +4.1% |
| Gross Profit | $18.67B$17.87B | +4.5% |
| R&D Expenses | $2.44B$2.30B | +6.1% |
| SG&A Expenses | $9.77B$9.74B | +0.2% |
| Operating Expenses | $27.37B$26.93B | +1.6% |
| Operating Income | $4.53B$3.65B | +24.2% |
| Interest Expense | $670.00M$826.00M | −18.9% |
| Net Income | $3.69B$2.37B | +55.7% |
| EPS (Basic) | $2.07$1.34 | +54.5% |
| EPS (Diluted) | $2.06$1.33 | +54.9% |
| Shares Outstanding (Basic) | 1.77B1.76B | +0.6% |
| Shares Outstanding (Diluted) | 1.78B1.77B | +0.6% |
05—Questions
Frequently Asked Questions
What were Abbott's primary growth drivers in 2019?
Abbott's growth in 2019 was primarily driven by strong performance in its Medical Devices segment, particularly in Diabetes Care (FreeStyle Libre), Structural Heart, Electrophysiology, and Heart Failure products. The Diagnostic Products segment also contributed significantly due to the adoption of its Alinity diagnostic systems and growth in Core Laboratory and Rapid Diagnostics. The Established Pharmaceutical Products segment saw growth driven by emerging markets, while the Nutritional Products segment benefited from new product introductions and global demand.
How did Abbott manage its debt following major acquisitions?
Abbott actively managed its debt following the significant acquisitions of St. Jude Medical and Alere. The company demonstrated a consistent strategy of debt reduction and refinancing. Throughout 2018 and 2019, Abbott repaid billions in debt, utilizing cash flow from operations and strategic debt management. By December 31, 2019, total debt was $18.1 billion, down from $27.9 billion at the end of 2017, reflecting successful debt reduction efforts.
What is Abbott's strategy for future growth?
Abbott's strategy for future growth centers on continued investment in product development and innovation across its four key segments. The company plans to expand market adoption and geographic reach for its diagnostic instruments, enhance its medical device portfolio in areas like diabetes care and structural heart, drive global growth in nutritionals with new science-based products, and expand its pharmaceutical offerings in emerging markets. A key focus is on developing next-generation technologies and products that address unmet medical needs.
How does Abbott address regulatory and compliance risks?
Abbott acknowledges that its development, manufacturing, marketing, and sale of products are subject to extensive government regulation globally. The company states that compliance with these complex regulations is costly and materially impacts its business. Failure to comply can lead to significant sanctions, including product recalls, suspensions, fines, and other penalties. Abbott expects the regulatory environment to continue requiring significant investment and expertise to ensure ongoing compliance.
06—Continue